{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:51:44Z","timestamp":1782903104092,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T00:00:00Z","timestamp":1441324800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Syst Biol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12918-015-0201-z","type":"journal-article","created":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T06:04:25Z","timestamp":1441346665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis"],"prefix":"10.1186","volume":"9","author":[{"given":"R. Joseph","family":"Bender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feilim","family":"Mac Gabhann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,4]]},"reference":[{"key":"201_CR1","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, O\u2019Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539\u201344.","journal-title":"J Clin Oncol"},{"key":"201_CR2","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542\u201350.","journal-title":"N Engl J Med"},{"key":"201_CR3","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon 2nd JE, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722\u20139.","journal-title":"J Clin Oncol"},{"key":"201_CR4","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103\u201311.","journal-title":"Lancet"},{"key":"201_CR5","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Cutsem Van","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499\u2013506.","journal-title":"J Clin Oncol"},{"key":"201_CR6","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1200\/JCO.2008.20.8876","volume":"27","author":"LA Mucci","year":"2009","unstructured":"Mucci LA, Powolny A, Giovannucci E, Liao Z, Kenfield SA, Shen R, et al. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol. 2009;27:5627\u201333.","journal-title":"J Clin Oncol"},{"key":"201_CR7","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","volume":"30","author":"WK Kelly","year":"2012","unstructured":"Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534\u201340.","journal-title":"J Clin Oncol"},{"key":"201_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","volume":"14","author":"IF Tannock","year":"2013","unstructured":"Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013;14:760\u20138.","journal-title":"Lancet Oncol"},{"key":"201_CR9","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"AM Brufsky","year":"2011","unstructured":"Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O\u2019Neill V, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29:4286\u201393.","journal-title":"J Clin Oncol"},{"key":"201_CR10","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396.","journal-title":"N Engl J Med"},{"key":"201_CR11","doi-asserted-by":"publisher","first-page":"a006502","DOI":"10.1101\/cshperspect.a006502","volume":"2","author":"S Koch","year":"2012","unstructured":"Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med. 2012;2:a006502.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"201_CR12","doi-asserted-by":"publisher","first-page":"a006718","DOI":"10.1101\/cshperspect.a006718","volume":"2","author":"G Neufeld","year":"2012","unstructured":"Neufeld G, Sabag AD, Rabinovicz N, Kessler O. Semaphorins in angiogenesis and tumor progression. Cold Spring Harb Perspect Med. 2012;2:a006718.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"201_CR13","doi-asserted-by":"publisher","first-page":"e61788","DOI":"10.1371\/journal.pone.0061788","volume":"8","author":"RJ Bender","year":"2013","unstructured":"Bender RJ, Mac Gabhann F. Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer. PLoS One. 2013;8:e61788.","journal-title":"PLoS One"},{"key":"201_CR14","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"201_CR15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1186\/1471-2164-14-690","volume":"14","author":"D Knezevic","year":"2013","unstructured":"Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical validation of the Oncotype DX prostate cancer assay -- a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14:690.","journal-title":"BMC Genomics"},{"key":"201_CR16","doi-asserted-by":"publisher","first-page":"e66855","DOI":"10.1371\/journal.pone.0066855","volume":"8","author":"N Erho","year":"2013","unstructured":"Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013;8:e66855.","journal-title":"PLoS One"},{"key":"201_CR17","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2012.46.4396","volume":"31","author":"MR Cooperberg","year":"2013","unstructured":"Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013;31:1428\u201334.","journal-title":"J Clin Oncol"},{"key":"201_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1593\/neo.05664","volume":"8","author":"TA Bismar","year":"2006","unstructured":"Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, et al. Defining aggressive prostate cancer using a 12-gene model. Neoplasia. 2006;8:59\u201368.","journal-title":"Neoplasia"},{"key":"201_CR19","doi-asserted-by":"crossref","first-page":"202ra122","DOI":"10.1126\/scitranslmed.3006408","volume":"5","author":"S Irshad","year":"2013","unstructured":"Irshad S, Bansal M, Castillo-Martin M, Zheng T, Aytes A, Wenske S, et al. A molecular signature predictive of indolent prostate cancer. Sci Transl Med. 2013;5:202ra122.","journal-title":"Sci Transl Med"},{"key":"201_CR20","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.1073\/pnas.1215870110","volume":"110","author":"CL Wu","year":"2013","unstructured":"Wu CL, Schroeder BE, Ma XJ, Cutie CJ, Wu S, Salunga R, et al. Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc Natl Acad Sci U S A. 2013;110:6121\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"201_CR21","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1200\/JCO.2004.05.158","volume":"22","author":"YP Yu","year":"2004","unstructured":"Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004;22:2790\u20139.","journal-title":"J Clin Oncol"},{"key":"201_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239\u201343.","journal-title":"Nature"},{"key":"201_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nm.1944","volume":"15","author":"W Liu","year":"2009","unstructured":"Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15:559\u201365.","journal-title":"Nat Med"},{"key":"201_CR24","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1371\/journal.pcbi.0020180","volume":"2","author":"F Mac Gabhann","year":"2006","unstructured":"Mac Gabhann F, Popel AS. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches. PLoS Comput Biol. 2006;2:e180.","journal-title":"PLoS Comput Biol"},{"key":"201_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00345-007-0152-0","volume":"25","author":"CW Reuter","year":"2007","unstructured":"Reuter CW, Morgan MA, Grunwald V, Herrmann TR, Burchardt M, Ganser A. Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. World J Urol. 2007;25:59\u201372.","journal-title":"World J Urol"},{"key":"201_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1152\/physiolgenomics.00181.2011","volume":"44","author":"LH Chu","year":"2012","unstructured":"Chu LH, Rivera CG, Popel AS, Bader JS. Constructing the angiome: a global angiogenesis protein interaction network. Physiol Genomics. 2012;44:915\u201324.","journal-title":"Physiol Genomics"},{"key":"201_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10585-013-9610-9","volume":"31","author":"E Lee","year":"2013","unstructured":"Lee E, Pandey NB, Popel AS. Pre-treatment of mice with tumor-conditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model. Clin Exp Metastasis. 2013;31:67\u201379.","journal-title":"Clin Exp Metastasis"},{"key":"201_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.humpath.2012.06.009","volume":"44","author":"M Tretiakova","year":"2013","unstructured":"Tretiakova M, Antic T, Binder D, Kocherginsky M, Liao C, Taxy JB, et al. Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays. Hum Pathol. 2013;44:495\u2013502.","journal-title":"Hum Pathol"},{"key":"201_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/sj.pcan.4500572","volume":"5","author":"AV Bono","year":"2002","unstructured":"Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis. 2002;5:123\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"201_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00345-009-0471-4","volume":"28","author":"A Erbersdobler","year":"2010","unstructured":"Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, et al. Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol. 2010;28:687\u201392.","journal-title":"World J Urol"},{"key":"201_CR31","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1158\/1078-0432.CCR-12-3606","volume":"19","author":"JR Schoenborn","year":"2013","unstructured":"Schoenborn JR, Nelson P, Fang M. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res. 2013;19:4058\u201366.","journal-title":"Clin Cancer Res"},{"key":"201_CR32","doi-asserted-by":"crossref","first-page":"169ra110","DOI":"10.1126\/scitranslmed.3005211","volume":"5","author":"MJ Aryee","year":"2013","unstructured":"Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med. 2013;5:169ra110.","journal-title":"Sci Transl Med"},{"key":"201_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0090-4295(99)00167-3","volume":"54","author":"JL Duque","year":"1999","unstructured":"Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 1999;54:523\u20137.","journal-title":"Urology"},{"key":"201_CR34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1046\/j.1365-2362.2003.01243.x","volume":"33","author":"GJ Caine","year":"2003","unstructured":"Caine GJ, Blann AD, Stonelake PS, Ryan P, Lip GY. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest. 2003;33:883\u201390.","journal-title":"Eur J Clin Invest"},{"key":"201_CR35","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.7314\/APJCP.2013.14.3.2053","volume":"14","author":"A Singh","year":"2013","unstructured":"Singh A, Gautam KA, Dalela D, Sankhwar S, Natu S, Sankhwar P, et al. Plasma vascular endothelial growth factors A and C in patients undergoing prostatic biopsy and TURP for suspected prostatic neoplasia. Asian Pac J Cancer Prev. 2013;14:2053\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"key":"201_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1634\/theoncologist.2011-0321","volume":"17","author":"PJ Saylor","year":"2012","unstructured":"Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, et al. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012;17:212\u20139.","journal-title":"Oncologist"},{"key":"201_CR37","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.1158\/1078-0432.CCR-08-3317","volume":"15","author":"A Fontana","year":"2009","unstructured":"Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res. 2009;15:4954\u201362.","journal-title":"Clin Cancer Res"},{"key":"201_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/pros.21472","volume":"72","author":"TT Tomic","year":"2012","unstructured":"Tomic TT, Gustavsson H, Wang W, Jennbacken K, Welen K, Damber JE. Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2. Prostate. 2012;72:705\u201312.","journal-title":"Prostate"},{"key":"201_CR39","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s10637-011-9722-5","volume":"30","author":"EK Beardsley","year":"2012","unstructured":"Beardsley EK, Hotte SJ, North S, Ellard SL, Winquist E, Kollmannsberger C, et al. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest New Drugs. 2012;30:1652\u20139.","journal-title":"Invest New Drugs"},{"key":"201_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2012.48.5268","volume":"32","author":"MD Michaelson","year":"2014","unstructured":"Michaelson MD, Oudard S, Ou YC, Sengelov L, Saad F, Houede N, et al. Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer. J Clin Oncol. 2014;32:76\u201382.","journal-title":"J Clin Oncol"},{"key":"201_CR41","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","volume":"31","author":"DC Smith","year":"2013","unstructured":"Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31:412\u20139.","journal-title":"J Clin Oncol"},{"key":"201_CR42","doi-asserted-by":"publisher","first-page":"7828","DOI":"10.1158\/0008-5472.CAN-08-1488","volume":"68","author":"JB Burton","year":"2008","unstructured":"Burton JB, Priceman SJ, Sung JL, Brakenhielm E, An DS, Pytowski B, et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008;68:7828\u201337.","journal-title":"Cancer Res"},{"key":"201_CR43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/pros.20276","volume":"65","author":"K Jennbacken","year":"2005","unstructured":"Jennbacken K, Vallbo C, Wang W, Damber JE. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate. 2005;65:110\u20136.","journal-title":"Prostate"},{"key":"201_CR44","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1182\/blood-2012-02-410076","volume":"120","author":"M Segarra","year":"2012","unstructured":"Segarra M, Ohnuki H, Maric D, Salvucci O, Hou X, Kumar A, et al. Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood. 2012;120:4104\u201315.","journal-title":"Blood"},{"key":"201_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0090-4295(94)80264-5","volume":"43","author":"M Aihara","year":"1994","unstructured":"Aihara M, Wheeler TM, Ohori M, Scardino PT. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology. 1994;43:60\u20136. discussion 66\u201367.","journal-title":"Urology"}],"container-title":["BMC Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12918-015-0201-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12918-015-0201-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12918-015-0201-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12918-015-0201-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T19:27:50Z","timestamp":1580758070000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsystbiol.biomedcentral.com\/articles\/10.1186\/s12918-015-0201-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,4]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["201"],"URL":"https:\/\/doi.org\/10.1186\/s12918-015-0201-z","relation":{},"ISSN":["1752-0509"],"issn-type":[{"value":"1752-0509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,4]]},"assertion":[{"value":"27 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"55"}}